Menu Search
Equities

Ascletis Pharma Inc

1672:HKG

Ascletis Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.00
  • Today's Change-0.04 / -3.85%
  • Shares traded1.71m
  • 1 Year change-45.36%
  • Beta0.8464
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Ascletis Pharma Inc grew revenues 4.63% from 54.09m to 56.60m while net income improved from a loss of 314.84m to a smaller loss of 144.72m.
Gross margin-125.17%
Net profit margin-2,561.69%
Operating margin-2,412.67%
Return on assets-10.47%
Return on equity-10.88%
Return on investment-10.85%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Ascletis Pharma Inc fell by 73.65m. However, Cash Flow from Investing totalled 149.85m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 144.16m for operations while cash used for financing totalled 81.50m.
Cash flow per share-0.2531
Price/Cash flow per share--
Book value per share2.37
Tangible book value per share2.35
More ▼

Balance sheet in CNYView more

Ascletis Pharma Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio24.38
Quick ratio24.31
Total debt/total equity0.0041
Total debt/total capital0.004
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.